SAN FRANCISCO, Nov. 15, 2022 (GLOBE NEWSWIRE) — Hagens Berman Urges Twist Bioscience Corporation (NASDAQ:TWST) Investors who have suffered significant losses Submit your losses now.

Twist Bioscience Corporation (NASDAQ:TWST) Investigation:

Twist claims that it is an innovative synthetic biology and genomics company that has developed a scalable DNA synthesis platform to industrialize the engineering of biology and that at the core of its platform is a proprietary technology that provides a new way to produce synthetic DNA by “writing” DNA pathways on a silicon chip.

Twist’s claims were seriously challenged on November 15, 2022 Scorpio Capital published a damning investigative report that concluded that Twist “[t]The latest miniaturized lab-on-a-chip scam, just like Theranos, Berkely Lights and other failures.”

Scorpio interviewed Twist’s ex-executives and production workers, customers and competitors and claims in his report that: (1) Twist is “a ticking time bomb that we believe resorts to a Worldcom-like accounting fraud;” (2) his “[p]The alleged Oregon ‘factory of the future’ that Twist is reportedly ramping up at ~100 million capex appears to be abandoned based on photographic and other evidence, leading us to believe it is an improper capitalization ploy. (3) “Twist’s reported gross margins of 45% are simply incredible, and we think they are actually negative;” (4) “[m]Several competitors internally refer to Twist’s price dumping and customer subsidy program as “Ponzi”; and (5) “Twist’s management is showing red flags, with suspicious transactions involving opaque Chinese offshore companies, and its largest IPO holders appear to be a cesspool of bad actors.”

In response, Twist’s stock price plummeted as much as 33% during intraday trading on Nov. 15.

“We are focused on investor losses and whether Twist will inform investors about its accounting and…